MARKET

NLTX

NLTX

Neoleukin Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.060
-0.050
-4.50%
Closed 16:00 05/20 EDT
OPEN
1.120
PREV CLOSE
1.110
HIGH
1.140
LOW
1.000
VOLUME
196.07K
TURNOVER
--
52 WEEK HIGH
11.10
52 WEEK LOW
0.9234
MARKET CAP
45.05M
P/E (TTM)
-0.9559
1D
5D
1M
3M
1Y
5Y
Neoleukin Therapeutics Announces First Patient Treated In Combination Arm Of Phase 1 Trial Evaluating NL-201 In Combination With KEYTRUDA (pembrolizumab)
eoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced treatment of
Benzinga · 6d ago
Neoleukin Therapeutics Announces First Patient Treated in Combination Arm of Phase 1 Trial Evaluating NL-201 in Combination with KEYTRUDA® (pembrolizumab)
SEATTLE, May 16, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced treatment of the first pati...
GlobeNewswire · 6d ago
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 807 companies reached new 52-week lows.
Benzinga · 05/11 16:28
--Guggenheim Adjusts Price Target for Neoleukin Therapeutics to $12 From $16, Maintains Buy Rating
MT Newswires · 05/10 14:22
BRIEF-Neoleukin Therapeutics Files For Offering Of 15.3 Million Shares Of Common Stock By Selling Stockholder - SEC Filing
reuters.com · 05/09 21:27
Neoleukin Therapeutics GAAP EPS of -$0.28 beats by $0.02
Neoleukin Therapeutics press release (NASDAQ:NLTX): Q1 GAAP EPS of -$0.28 beats by $0.02. “During the first quarter of 2022 our dedicated team at Neoleukin has been focused on execution of
Seekingalpha · 05/09 21:19
Neoleukin Therapeutics to Present at Upcoming Investor Conferences
SEATTLE, May 05, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D...
GlobeNewswire · 05/05 12:00
Stocks That Hit 52-Week Lows On Monday
    On Monday, 466 companies hit new 52-week lows.
Benzinga · 04/18 15:40
More
No Data
Learn about the latest financial forecast of NLTX. Analyze the recent business situations of Neoleukin Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

57.14%Strong Buy
42.86%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average NLTX stock price target is 17.71 with a high estimate of 25.00 and a low estimate of 6.00.
High25.00
Average17.71
Low6.00
Current 1.060
EPS
Actual
Estimate
-0.24-0.18-0.12-0.06
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 111
Institutional Holdings: 27.19M
% Owned: 63.98%
Shares Outstanding: 42.50M
TypeInstitutionsShares
Increased
24
1.58M
New
14
670.55K
Decreased
26
1.04M
Sold Out
13
1.28M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.65%
Pharmaceuticals & Medical Research
+1.64%
Key Executives
Non-Executive Chairman/Independent Director
Todd Simpson
President/Chief Executive Officer/Chief Financial Officer/Director
Jonathan Drachman
Senior Vice President/General Counsel
Donna Cochener
Senior Vice President
Carl Walkey
Vice President
Bill Arthur
Other
Priti Patel
Independent Director
Martin Babler
Independent Director
M. Cantey Boyd
Independent Director
Erin Lavelle
Independent Director
Sarah Noonberg
Independent Director
Rohan Palekar
No Data
No Data
About NLTX
Neoleukin Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in providing immunotherapies for cancer, inflammation, and autoimmunity using de novo protein design technology. The Company uses computational methods to design proteins that demonstrate specific pharmaceutical properties. Its primary areas of focus are oncology, inflammation and autoimmunity. Its technology, Neoleukin platform, uses a set of advanced computational algorithms and methods to design functional de novo proteins. Neoleukin’s lead program, NL-201, is a computationally designed de novo protein therapeutic. NL-201 is designed for use as a single-agent or in combination with complementary therapeutic modalities. NL-201 has also shown promise in combination with allogenic cell therapy to expand and maintain populations of transplanted CAR-T and NK cells.

Webull offers kinds of Neoleukin Therapeutics Inc stock information, including NASDAQ:NLTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NLTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NLTX stock methods without spending real money on the virtual paper trading platform.